Acumen Pharmaceuticals, Inc. — Director's Dealing 2021

Dec 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Acumen Pharmaceuticals, Inc. (ABOS)
CIK: 0001576885
Period of Report: 2021-11-30

Reporting Person: OConnell Daniel Joseph (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-30	Common Stock	M	1118	$4.47	Acquired	2685	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-30	Stock Option (Right to Buy)	$4.47	M	1118	Disposed	2021-12-01	Common Stock (1118)	Direct

Footnotes

F1: Immediately exercisable.